Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.
Access advanced solid tumors specialists in Nashville at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced solid tumors treatment provided free
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransfe
Sponsor: Servier Bio-Innovation LLC
Check if you qualify for this advanced solid tumors clinical trial in Nashville, TN
If you're searching for advanced solid tumors treatment options in Nashville, TN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.